Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future

Novo Nordisk CEO Mike Doustdar, one year into a corporate restructuring, stated that investors underestimate the potential of the company's drug pipeline. The statement was made as the pharmaceutical company faces investor scrutiny regarding its future prospects. Doustdar did not specify which drugs or timelines he was referencing.

Next story